Bionano Genomics is a medical instruments & supplies business based in the US. Bionano Genomics shares (BNGO) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.21 – a decrease of 18.17% over the previous week. Bionano Genomics employs 344 staff and has a trailing 12-month revenue of around $36.6 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.21 |
|---|---|
| 52-week range | $0.24 - $2.27 |
| 50-day moving average | $0.38 |
| 200-day moving average | $0.75 |
| Wall St. target price | $1.90 |
| PE ratio | 0.0268 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $9.89 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.2246 from 2024-11-19
| 1 week (2024-11-14) | -12.23% |
|---|---|
| 1 month (2024-10-21) | -29.92% |
| 3 months (2024-08-21) | -59.16% |
| 6 months (2024-05-21) | -78.61% |
| 1 year (2023-11-21) | -84.51% |
|---|---|
| 2 years (2022-11-21) | -99.00% |
| 3 years (2021-11-19) | 44.1 |
| 5 years (2019-11-21) | 9.799 |
Valuing Bionano Genomics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Bionano Genomics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Bionano Genomics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 0x. In other words, Bionano Genomics shares trade at around 0x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
| Revenue TTM | $36.6 million |
|---|---|
| Gross profit TTM | $5.9 million |
| Return on assets TTM | -32.64% |
| Return on equity TTM | -138.33% |
| Profit margin | 0% |
| Book value | $1.14 |
| Market Capitalization | $25.4 million |
TTM: trailing 12 months
We're not expecting Bionano Genomics to pay a dividend over the next 12 months.
Bionano Genomics's shares were split on a 1:10 basis on 6 August 2023 . So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Bionano Genomics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Bionano Genomics shares which in turn could have impacted Bionano Genomics's share price.
Over the last 12 months, Bionano Genomics's shares have ranged in value from as little as $0.24 up to $2.27. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Bionano Genomics's is 2.376. This would suggest that Bionano Genomics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA. The company also provides Saphyr and Bionano compute servers; and VIA software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.